(Q39866119)

15 September 2017

1 reference

title

The immunology of liver disease (English)

1 reference

15 September 2017

0 references

S Sherlock

1

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 November 1970

1 reference

American Journal of Medicine

15 September 2017

published in

1 reference

15 September 2017

volume

49

1 reference

15 September 2017

page(s)

693-706

1 reference

15 September 2017

cites work

γ-GLOBULIN METABOLISM

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Electrophoretic studies in liver disease. II. Gamma globulin in chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

ACTIVE 'JUVENILE' CIRRHOSIS CONSIDERED AS PART OF A SYSTEMIC DISEASE AND THE EFFECT OF CORTICOSTEROID THERAPY

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Dysimmunoglobulinemia associated with hepatobiliary disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Significance of immunologic reactions for the diagnosis and pathogenesis of chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Immunoglobulins in chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Immunoglobulins in viral hepatitis and active alcoholic liver-disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Immunoglobulin changes in disease: quantitation on the basis of heavy polypeptide chains, IgG (gammaG), IgA (gammaA), and IgM (gammaM), and of light polypeptide chains, type K (I) and type L (II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

[Quantitative serum immunoglobulin determinations in inflammatory liver diseases. II. Chronic inflammatory liver diseases]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

IMMUNOCYTOCHEMICAL AND SEROLOGIC OBSERVATIONS IN PRIMARY BILIARY CIRRHOSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Significance of immunoglobulins for the diagnosis and evaluation of the course of liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

SEROLOGICAL ABNORMALITIES IN PATIENTS WITH LIVER DISEASE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

An autoimmune reaction against human tissue antigens in certain acute and chronic diseases. I. Serological investigations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Occurrence of complement-fixing antibodies reactive with normal tissue constituents in normal and disease states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Complement fixing reactions with liver tissue in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

SEROLOGICAL TESTS IN DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Serological and histological diagnosis of primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Mitochondrial antibodies in primary biliary cirrhosis. I. Localization of the antigen to mitochondrial membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Immunologic phenomena in liver diseases: significance of mitochondrial antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Antibody to smooth muscle in patients with liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Autoimmune hepatitis. Immunofluorescence reactions with cytoplasm of smooth muscle and renal glomerular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

RENAL INVOLVEMENT IN ACTIVE "JUVENILE" CIRRHOSIS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Impaired delayed hypersensitivity in primary biliary cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Lymphocyte stimulation and chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

[Differential reaction of lymphocytes to phytohemagglutinin (PHA) in liver diseases].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Immunological and histological studies in primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

A unified concept of autoimmune hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

7 January 2021

Autoallergic Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Australia antigen in acute and chronic liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Australia antigen in chronic active liver disease with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Australia Antigen in Chronic Hepatitis in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Australia antigen and smooth-muscle antibody in acute and chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Immune complexes in hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Virus-like antigen, antibody, and antigen-antibody complexes in hepatitis measured by complement fixation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Complement-fixation test for Australia antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Antimitochondrial antibodies in jaundice following drug administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Hepatitis-associated antigen in chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Lymphocyte Stimulation Induced by Halothane in Patients with Hepatitis Following Exposure to Halothane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

DRUG-INDUCED LIVER DISEASE: A PENALTY FOR PROGRESS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Recurrent hepatitis attributable to halothane sensitization in an anesthetist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Hepatitis After Exposure to Halothane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Effect of corticosteroid therapy on bromsulphthalein excretion in active chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Augmentation of albumin but not fibrinogen synthesis by corticosteroids in patients with hepatocellular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Long-term results of therapy in patients with chronic liver disease associated with hypergammaglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Treatment of primary biliary cirrhosis with azothioprine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Transplantation of the liver in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Alpha-1 fetoglobulin in the diagnosis of human hepatoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

Antigenic structure of chemically-induced hepatomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2870%2980134-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(70)80134-6

1 reference

15 September 2017

1 reference